Treatment of Relapsed or Refractory B-cell Malignancies by CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells

Trial Profile

Treatment of Relapsed or Refractory B-cell Malignancies by CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; B-cell leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Nov 2017 Planned number of patients changed from 20 to 50.
    • 10 Jun 2017 Biomarkers information updated
    • 23 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top